Multi-target TMS for Schizophrenia Negative Symptoms
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 45 years old?
Source: NCT07559084, who can take part
Where in China
- Shanghai Mental Health CenterShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Mental Health Center
- Trial code
- NCT07559084
- Record updated
- 10 September 2026
- Original description
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.Read full original descriptionShow less
Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.
Inclusion: Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center; Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment; Male or female aged 16-45 years; Education duration ≥ 9 years; Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit; Participants and their guardians can understand and sign written informed consent; Total score on the PANSS Negative Symptom subscale (PANSS-N) > 15, and at least one item score ≥ 3.
Exclusion: Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline; Current or lifetime psychiatric disorders as determined by SCID-5 assessment; Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions; No history of modified electroconvulsive therapy (mECT) within the past 6 months; Pregnant or breastfeeding women; Intellectual disability (IQ < 70).